Skip to main content

Table 2 Bivariate and multivariate analysis of factors associated with adverse drug events among study participants on dolutegravir-based regimen at ISS clinic-MRRH

From: Prevalence and factors associated with adverse drug events among patients on dolutegravir-based regimen at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital, Uganda: a mixed design study

Variables

Recorded experience of ADE

Bivariate odds ratio (95% CI)

p-value

Multivariate odds (95% CI)

p-value

Yes (%)

No (%)

Sex

 Male

62 (50.0)

161 (64.1)

1.789 (1.156–2.768)

0.009*

1.571 (1.433–1.984)

0.031*

 Female

62 (50.0)

90 (35.9)

1.0

 

1.0

 

Age

 20–29 years

5 (4.0)

11 (4.4)

1.441 (0.432–4.810)

0.552

  

 30–39 years

11 (8.9)

44 (17.5)

2.621 (1.089–6.307)

0.032*

  

 40–49 years

44 (35.5)

84 (33.5)

1.251 (0.631–2.478)

0.521

  

 50–59 years

45 (36.3)

83 (33.1)

1.208 (0.610–2.392)

0.587

  

  ≥ 60 years

19 (15.3)

29 (11.6)

1.0

   

Employment status

 Employed

85 (68.5)

197 (78.5)

1.674 (1.032–2.716)

0.037*

  

 Unemployed

39 (31.5)

54 (21.5)

1.0

   

Meals eaten before swallowing medicines

 Non-fatty meals

35 (28.2)

50 (19.9)

0.571 (0.335–0.976)

0.040*

  

 Plant based

11 (8.9)

22 (8.8)

0.800 (0.363–1.762)

0.580

  

 Animal based

24 (19.4)

44 (17.5)

0.733 (0.407–1.322)

0.302

  

 Plant and animal

54 (43.5)

135 (53.8)

1.0

   

Duration since HIV diagnosis

  < 5 years

12 (9.7)

41 (16.3)

3.417 (1.327–8.795)

0.011*

  

 5–10 years

27 (21.8)

93 (37.1)

3.444 (1.525–7.779)

0.003*

  

 11–15 years

69 (55.6)

101 (40.2)

1.464 (0.686–3.122)

0.324

  

  > 15 years

16 (12.9)

16(6.4)

1.0

   

WHO staging at entry into care

 Stage one

45 (36.3)

115 (45.8)

4.472 (1.757–11.386)

0.002*

4.586 (1.649–12.754)

0.004*

 Stage two

35 (28.2)

80 (31.9)

4.000 (1.539–10.396)

0.004*

4.536 (1.611–12.776)

0.004*

 Stage three

30 (24.2)

48 (19.1)

2.800 (1.050–7.469)

0.040*

3.638 (1.262–10.488)

0.017*

 Stage four

14 (11.3)

8 (3.2)

1.0

 

1.0

 

Viral load at initiation of DTG-based regimen

 Undetectable

110 (88.7)

182 (72.5)

0.336 (0.180–0.625)

0.001*

0.324 (0.1167–0.629)

0.001*

 Detectable

14 (11.3)

69 (27.5)

1.0

 

1.0

 
  1. Statistically significant P values less than 0.05 of ADE associated factors at multivariate analysis including sex, WHO staging at entry into care and viral load at initiation of DTG-based regimen
  2. *Significance, less than 0.05; %, percentage; ADE, adverse drug event; COR, crude odds ratio; AOR, Adjusted odds ratio; CI, confidence interval; HIV, human immunodeficiency virus; WHO, world health organization; DTG, dolutegravir; ART; < , less than; > , greater than; ≥ greater than or equal to